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JPGN  Volume 64, NABSTRACT
elicobacter pylori infection is acquired in childhood andBackground: Because of the changing epidemiology of Helicobacter pylori
infection and low efficacy of currently recommended therapies, an update of
the European Society for Paediatric Gastroenterology Hepatology and
Nutrition/North American Society for Pediatric Gastroenterology, Hepatol-
ogy and Nutrition recommendations for the diagnosis and management of H
pylori infection in children and adolescents is required.
Methods: A systematic review of the literature (time period: 2009–2014) was
performed. Representatives of both societies evaluated the quality of evidence
using GRADE (Grading of Recommendation Assessment, Development, and
Evaluation) to formulate recommendations, which were voted upon and
finalized using a Delphi process and face-to-face meeting.
Results: The consensus group recommended that invasive diagnostic testing for
H pyloribe performed only when treatment will be offered if tests are positive. To
reach the aim of a 90% eradication rate with initial therapy, antibiotics should be
tailored according to susceptibility testing. Therapy should be administered for
14 days, emphasizing strict adherence. Clarithromycin-containing regimens
should be restricted to children infected with susceptible strains. When
antibiotic susceptibility profiles are not known, high-dose triple therapy with
proton pump inhibitor, amoxicillin, and metronidazole for 14 days or bismuth-
based quadruple therapy is recommended. Success of therapy should be
monitored after 4 to 8 weeks by reliable noninvasive tests.
Conclusions: The primary goal of clinical investigation is to identify the
cause of upper gastrointestinal symptoms rather than H pylori infection.
Therefore, we recommend against a test and treat strategy. Decreasing
eradication rates with previously recommended treatments call for changes
to first-line therapies and broader availability of culture or molecular-based
testing to tailor treatment to the individual child.
Key Words: adolescents, antibiotic susceptibility, 13C-urea breath test,
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and gastric cancer (1). In comparison with adults, children and
adolescents, however, infrequently develop these complications ofremains an important cause of peptic ulcer disease (PUD)
infection. Furthermore H pylori infection in early childhood may be
associated with immunologic benefits later in life (2).
The updated recommendations were extensively discussed in
the light of decreasing efficacy of H pylori eradication therapy in
children and the rising prevalence of antibiotic-resistant strains.
Although H pylori infection is always associated with microscopic
gastric inflammation, the overwhelming majority of H pylori–
infected children are asymptomatic. Studies in children do not
support a role for H pylori infection in functional disorders such
as recurrent abdominal pain (3). Therefore in children the decision
to investigate and treat the infection should be supported by a clear
benefit for the individual child.
There is renewed hope in the potential for primary prevention
of infection based on the results of a recent vaccine study in Chinese
children (4). Optimization of the vaccine strategy is, however,
required to ensure long-lasting protection. Furthermore, additional
studies demonstrating efficacy in different geographic regions are
also needed before this vaccination strategy can be adopted in
clinical practice.
The recommended goal for H pylori treatment is an eradica-
tion rate of at least 90% to avoid further investigations and
antibiotic use (5). First-line therapies recommended in previous
guidelines have unacceptable treatment failures rates (6). Thus,
based on the declining prevalence of the infection in some
countries, and the ineffectiveness of previously recommended
first-line eradication therapies, European Society for Paediatric
Gastroenterology Hepatology and Nutrition (ESPGHAN) and
North American Society for Pediatric Gastroenterology, Hepatol-
ogy and Nutrition (NASPGHAN) determined that updated
yySPGHAN. All rights reserved.
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TABLE 1. Guideline recommendations
Synopsis of recommendations
1. We recommend that the primary goal of clinical investigation of gastrointestinal symptoms should be to determine the underlying cause of the symptoms and
not solely the presence of H pylori infection.
2a. We recommend that during endoscopy additional biopsies for RUT and culture should only be taken if treatment is likely to be offered if infection is
confirmed.
2b. We suggest that if H pylori infection is an incidental finding at endoscopy, treatment may be considered after careful discussion of the risks and benefits of H
pylori treatment with the patient/parents.
2c. We recommend against a ‘‘test and treat’’ strategy for H pylori infection in children.
3. We recommend that testing for H pylori be performed in children with gastric or duodenal ulcers. If H pylori infection is identified then treatment should be
advised and eradication be confirmed.
4. We recommend against diagnostic testing for H pylori infection in children with functional abdominal pain.
5a. We recommend against diagnostic testing for H pylori infection as part of the initial investigation in children with iron deficiency anemia.
5b. We suggest that in children with refractory IDA in which other causes have been ruled out, testing for H pylori during upper endoscopy may be considered.
6. We suggest that noninvasive diagnostic testing for H pylori infection may be considered when investigating causes of chronic immune thrombocytopenic
purpura (ITP).
7. We recommend against diagnostic testing for H pylori infection when investigating causes of short stature.
8. We recommend that before testing for H pylori, waiting at least 2 weeks after stopping proton pump inhibitor (PPI) and 4 weeks after stopping antibiotics.
9a. We recommend that the diagnosis of H pylori infection should be based on either (a) histopathology (H pylori–positive gastritis) plus at least 1 other
positive biopsy-based test or (b) positive culture.
9b. We recommend that for the diagnosis of H pylori infection at upper gastrointestinal endoscopy, at least 6 gastric biopsies be obtained.
10. We recommend against using antibody-based tests (IgG, IgA) for H pylori in serum, whole blood, urine, and saliva in the clinical setting.
11. We recommend that antimicrobial sensitivity be obtained for the infecting H pylori strain (s), and eradication therapy tailored accordingly.
12. We recommend that the effectiveness of first-line therapy be evaluated in national/regional centers.
13. We recommend that the physician explain to the patient/family the importance of adherence to the anti–H pylori therapy to enhance successful eradication.
14. We recommend first-line therapy for H pylori infection as listed in Table 2.
15. We recommend that the outcome of anti–H pylori therapy be assessed at least 4 weeks after completion of therapy using one of the following tests.
(a) The 13C-urea breath (13C-UBT) test or (b) a 2-step monoclonal stool antigen test.
16. We recommend that when H pylori treatment fails, rescue therapy should be individualized considering antibiotic susceptibility, the age of the child, and
available antimicrobial options.
IDA ¼ iron deficiency anemia; RUT ¼ rapid urease test.
Jones et al JPGN  Volume 64, Number 6, June 2017guidelines for H pylori infection in children and adolescents
were required.
These guidelines apply only to pediatric patients, defined as
children and adolescents below 18 years of age. Recommendations
for children and adolescents may differ from recent guidelines for
adults because of a different risk-benefit ratio depending on age
and the fact that some antibiotics are not released or licensed for
the pediatric population. The guidance in this document does not
indicate an exclusive course of treatment or serve as a standard
of medical care. Variations, taking into account individual and
national circumstances, may be appropriate. This applies parti-
cularly to developing countries with high H pylori infection rates




Joint ESPGHAN/NASPGHAN guidelines were developed for
the management of H pylori infection in children and adolescents in
2009 and published in 2011 (6). Based on new clinical knowledge and Copyright © ESPGHAN and NA
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992in particular, increasing challenges with eradication therapy, NASP-
GHAN and ESPGHAN agreed to review the current literature to
provide updated guidelines for the management of H pylori infection
in the pediatric population in North America and Europe.
Literature Review
A systematic literature search using PubMed, MEDLINE,
EMBASE, Cochrane Library, and Scopus databases between Octo-
ber 1, 2009 to September 2014 using the following MESH terms
((‘‘Adolescent’’[Mesh] OR ‘‘Child’’[Mesh] OR ‘‘Infant’’[Mesh]
OR ‘‘Minors’’[Mesh] OR ‘‘Pediatrics’’[Mesh]) AND (‘‘Helicobac-
ter pylori’’[Mesh] OR ‘‘Helicobacter Infections’’[Mesh])) (K.G.).
Studies were restricted to humans and conference abstracts and non-
English literature were excluded.
Review, Grading of Evidence, and Consensus
Process
The consensus group consisted of an international group
of experts including pediatric gastroenterologists, clinicalSPGHAN. All rights reserved.
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interest for 24 months prior using the societies’ conflict of interest
Web-based platforms. The consensus group was divided into 4
working groups (who to test, how to test, who to treat, and how to
treat). Each working group reviewed the literature for their assigned
topic and produced tables that rated the quality of evidence and
strength of the recommendations using GRADE (Grading of
Recommendation Assessment, Development, and Evaluation) (7).
There were 2 levels of recommendations: strong or weak. The
quality of evidence for each statement was graded as high, mod-
erate, or low (A, B, and C). For most of the pediatric studies the
evidence was low. In the absence of high-level evidence in the
pediatric literature, studies in adults were considered and extrapol-
ation performed, when appropriate. The tables and the referenced
literature as full papers were made available to all authors on the
Web-based guideline platform. The working groups developed
initial recommendations based on the evidence. The entire group
then voted anonymously on the initial statements using the Web-
based platform. Suggestions for changes to the statements were
incorporated and the statements were voted upon a second time
before the face-to-face meeting.
In May 2015, a one-day, face-to-face meeting was held in
Amsterdam. At the meeting, representatives from each of the groups
presented the relevant data, the GRADE recommendations were
reviewed, and inclusion and wording of the statements finalized.
Lastly, the consensus group voted on their level of agreement with
each of the statements. A statement was accepted if there was>75%
agreement. Per the GRADE system, ‘‘we recommend’’ was
employed if the assigned strength of the recommendation was
strong while ‘‘we suggest’’ was employed if the strength of the
recommendation was weak or conditional.
Manuscript
Each of the working groups provided a summary of the
written background evidence for the statements, which was then
used to draft the initial manuscript by the co-chairs (N.L.J., S.K.).
The manuscript was circulated to the consensus group for revisions
and then to the members of ESPGHAN and NASPGHAN before
submission for publication.
Funding Sources
ESPGHAN and NASPGHAN were the sole funding sources
for the development of the guidelines.
Recommendations
Table 1 provides a synopsis of the new recommendations.
Listed below are the individual recommendations, the GRADE
rating, voting results, and a discussion of the supporting evidence.
Practical practice points are included for each recommendation to aid
the physician in management decisions for the individual patient.
Recommendation 1: We recommend that the primary
goal of clinical investigation of gastrointestinal symp-
toms should be to determine the underlying cause of
the symptoms and not solely the presence of H
pylori infection.
GRADE: This statement reflects consensus opinion
on the philosophy of care for children rather than Copyright © ESPGHAN and NA




SPn the absence of PUD herein defined as gastric or duodenal
lceration or erosions, eradication of H pylori infection is not
expected to result in improvement of symptoms.COMMENT:
Since the last guidelines in 2009 (6), no new data support a
role for H pylori infection as a cause of symptoms in the absence of
PUD. In cases of abdominal pain in which an organic cause is
considered, a diagnostic upper endoscopy rather than noninvasive
testing for H pylori should be performed. This recommendation
remains unchanged from the previous guidelines.
Recommendation 2a:
We recommend that during endoscopy additional
biopsies for rapid urease test (RUT) and culture should
only be taken if treatment is likely to be offered if
infection is confirmed.
GRADE: As there are no specific studies addressing
this statement, no GRADE was assigned. Agreement:
86%.
Recommendation 2b:
We suggest that if H pylori infection is an incidental
finding at endoscopy, treatment may be considered
following careful discussion with the patient/parents.
GRADE: Weak recommendation. Quality of evi-
dence: low. Agreement: 86%.
Practice Points1. I
(
f during endoscopy antral nodularity without mucosal lesions
gastric or duodenal erosions/ulcer) is visualized, biopsies for
RUT and culture to diagnose H pylori infection and guide
treatment should only be taken by the endoscopist if treatment is
likely to be offered upon confirmation of infection.
Upon offering anti–H pylori treatment to children without PUD2.
(as outlined in Tables 2–4), physicians should explain that H
pylori infection is not likely to be the cause of the symptoms, and
therefore H pylori treatment would not be expected to cure their
symptoms. Discussion with parents or older children should
include the potential risk of developing complications related to
infection (PUD, gastric cancer) later in life weighed against the
potential risks of treatment (eg, treatment failure, adverse
effects of antibiotic use such as diarrhea, cramps, or negative
alterations to the gut microbiome).COMMENT:
Diagnostic investigation for H pylori in children is justified
only in cases in which the expected benefits outweigh the costs and
risks of testing and subsequent treatment. Based on current evi-
dence, treatment to eliminate H pylori infection is not expected
to improve symptoms in children, except in cases of PUD (2).
Therefore, if peptic lesions are not clinically suspected or ident-
ified by endoscopy, invasive diagnostic testing for the sole
purpose of detecting H pylori infection should not be undertaken.GHAN. All rights reserved.
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TABLE 2. Recommended options for first-line therapy for H pylori infection
H pylori antimicrobial susceptibility Suggested treatment
Known
Susceptible to CLA and to MET PPI-AMO-CLA 14d with standard dose

(Table 4)
Resistant to CLA, susceptible to MET PPI-AMO-MET 14d or bismuth-basedy
Resistant to MET, susceptible to CLA PPI-AMO-CLA 14d or bismuth-basedy
Resistant to CLA and to MET PPI-AMO-MET 14d with high dose for amoxicillin (Table 5) or bismuth-basedy,z
Unknown
High-dose (Table 5) PPI-AMO-MET 14d or bismuth-basedy,z
AMO¼ amoxicillin; CLA¼ clarithromycin; MET¼metronidazole; PPI¼ proton pump inhibitor.
Or sequential therapy for 10d (see recommendation 14).
yIn the case of penicillin allergy: if the strain is susceptible to CLA and MET, use standard dose triple therapy with MET in place of AMO; if the strain is
resistant to CLA, then use bismuth-based therapy with tetracycline instead of AMO if older than 8 years.
zOr concomitant therapy (PPI-AMO-MET-CLA) for 14d (see comment on concomitant therapy in recommendation 14).
Jones et al JPGN  Volume 64, Number 6, June 2017H pylori–associated gastritis may, however, be an incidental
histopathologic finding during upper endoscopy performed for
unrelated indications such as the diagnosis of inflammatory bowel
disease, or celiac disease, especially in areas with a high prevalence
of infection. The finding of H pylori–associated gastritis without
duodenal or gastric mucosal lesions poses a dilemma for the
pediatric gastroenterologist about whether to recommend eradica-
tion treatment. H pylori–associated gastritis without PUD, rarely
gives rise to symptoms or progresses to more serious disease
complications during childhood (2). The lower risk of compli-
cations in children may be in part explained by a different immune
response toward the infection. In comparison with adults, gastric
biopsies obtained from children infected with H pylori show a
decrease in inflammation. In addition, an increase in the number of
immunosuppressive T regulatory (Treg) cells along with an anti-
inflammatory IL-10 instead of a proinflammatory IL-17 cytokine
response is detected (8,9).
In addition, in high-prevalence communities the reinfection
rate in young children after successful eradication may be Copyright © ESPGHAN and NA










15–24 kg 20 20
25–34 kg 30 30
>35 kg 40 40
Amoxicillin 15–24 kg 500 500
25–34 kg 750 750
>35 –kg 1000 1000
Clarithromycin 15–24 kg 250 250
25–34 kg 500 250
>35 kg 500 500
Metronidazole 15–24 kg 250 250
25–34 kg 500 250y
>35 kg 500 500
Bismuthz <10 years 262 QID
>10 years 524 QID
PPI¼ proton pump inhibitor.
The doses of the different proton pump inhibitors are not equivalent. See
comment on PPI in recommendation 14.
yIf oral suspension of metronidazole is employed, the dose can be divided
to be equal every 12 hours.
zBismuth in the United States and Canada comes as bismuth subsalicylate.
994significant. A study from Bolivia in a high-prevalence, low-income
population showed a reinfection rate 1 year after successful therapy
of 20% in children younger than 10 years, compared to 8% in older
children and adolescents (10). These figures are higher than rein-
fection rates in adults patients living in high-prevalence countries in
Latin America (11% reinfection rate after 1 year) (11) or children
and adolescents living in a low-prevalence country like Germany
(2.3% per year) (12).
The risk of H pylori–associated cancer or mucosa-
associated lymphoid tissue-lymphoma during childhood is
extremely low in Europe and North America. The risk/benefit
ratio may vary in different regions. In areas with a high rate of
gastric cancer such as China or Japan, the benefits of treatment to
reduce the risk of gastric cancer development may outweigh the
risks of treatment (13). In Western countries there is epidemiologic
evidence that H pylori infection, especially in young children,
may be associated with a reduced prevalence of allergic disease
(14–18). Higher prevalence of H pylori infection may, however, be
a surrogate marker for host demographics that could confer pro-
tection against autoimmunity and allergy. Therefore, although
there is evidence for a causal relationship in mouse models of
asthma and inflammation (18), prospective randomized interven-
tion studies in humans are needed to demonstrate a causal relation-
ship. There are currently no good biomarkers to identify the small
number of individuals that will go on to develop more severe
sequelae of infection later in life. Thus, the decision to treat H
pylori–associated gastritis in the absence of PUD when found as
an incidental finding at upper endoscopy should be carefully
discussed with the patient and family taking into consideration
the potential risk and benefits of treatment in the individual
patient.
Recommendation 2c: We recommend against a ‘‘test
and treat’’ strategy for H pylori infection in children.
GRADE: Strong recommendation. Quality of evi-




SPGhe goal of clinical investigation is to detect the cause of the
hild’s symptoms. Since current evidence indicates that H
pylori infection does not cause symptoms in the absence of
PUD, performing a noninvasive test to detect infection and
treat if the test is positive is not warranted.HAN. All rights reserved.
www.jpgn.org
TABLE 4. High dosing regimen for amoxicillin




JPGN  Volume 64, Number 6, June 2017 Guidelines for the Management of H pylori in Children and AdolescentsCOMMENT:
Since the last guidelines in 2009, there is no evidence to
support a ‘‘test and treat’’ strategy for H pylori infection in children.
Therefore, this recommendation against noninvasive testing and
treating in case of positive results remains unchanged from the
previous guidelines.
Recommendation 3: We recommend that testing for
H pylori be performed in children with gastric or
duodenal PUD. If H pylori infection is identified then
treatment should be administered and eradication
confirmed.
GRADE: Strong recommendation. Quality of evi-












wwwlthough H pylori infection is only one of several causes of
astric or duodenal erosions/ulceration in children, it is a
treatable condition. Eradication of infection prevents ulcer
recurrence. If erosions, ulcers, or scarring are visualized
during upper endoscopy, biopsies (as outlined in Recom-
mendation 9) should be taken to identify the presence of H
pylori infection.
Proton pump inhibitor (PPI) monotherapy may be continued
after eradication therapy for another 2 to 4 weeks in patients
with PUD.
Successful H pylori eradication is associated with cure
of PUD and very low risk of relapse. Therefore monitoring
the success of therapy is mandatory in these patients 4 to
6 weeks after stopping antibiotics and at least 2 weeks
after stopping PPI therapy. In case of eradication failure, Copyright © ESPGHAN and NASPG
5. Rescue therapies in pediatric patients who failed therapy
Initial antibiotic susceptibility Past treatment regimen
Clarithromycin and metronidazole
susceptible
Triple therapy using amoxicillin
clarithromycin





Clarithromycin resistant Triple therapy using metronidaz
Metronidazole resistant Triple therapy using clarithrom
Primary antimicrobial
susceptibility unknown
Triple therapy or sequential the
adolescents levofloxacin or tetracycline may be considered.
.jpgn.orgthe patient should receive rescue therapy as outlined in
Table 5.
Intake of acid-suppressive drugs and antibiotics decrease the
sensitivity of all biopsy-based tests for H pylori (see
recommendation 8). Before endoscopy an accurate history
for drug intake during the previous 4 weeks should be
obtained from the child and caregivers.
Active bleeding decreases the sensitivity of biopsy-based tests
for infection.
If false-negative results of invasive tests are suspected due to
drug intake or active bleeding, noninvasive tests may be
helpful to determine whether the ulcer may be related to H
pylori infection.
Successful H pylori eradication is associated with long-term
cure of PUD in children. Therefore monitoring the success of
therapy 4 to 6 weeks after stopping therapy and re-treatment
in case of failure is mandatory in these patients.COMMENT:
Although the rates of H pylori infection are declining,
infection still remains an important cause of PUD (19). Further-
more, eradication of infection is associated with long-term cure of
PUD in children.
In the previous joint guidelines, a weak recommendation for
testing for H pylori infection in the setting of a first-degree relative
with gastric cancer was included (6). As there remains no evidence
for this recommendation, and the question rarely arises in clinical
pediatric gastroenterology practice, it was decided to remove this
recommendation from the current guidelines.
Recommendation 4
We recommend against diagnostic testing for H pylori
infection in children with functional abdominal
pain disorders.
GRADE: Strong recommendation. Quality of evi-
dence: high. Agreement: 100%.
Practice Points
 Children with recurrent abdominal pain without any alarm
signs or symptoms most likely have functional pain
independent of H pylori status.HAN. All rights reserved.
Rescue treatment
and Triple therapy using amoxicillin and metronidazole
Triple therapy using amoxicillin and clarithromycin
Consider performing a second endoscopy and use
a tailored treatment for 14d ; or treat like
double resistance (Table 2)

ole Treat like double resistance (Table 2)

ycin Consider performing a second endoscopy and use a
tailored treatment for 14 days or treat like double
resistance (Table 2)

rapy Consider performing a second endoscopy to assess
secondary antimicrobial susceptibility; or treat like
double resistance (Table 2)

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996larm signs include persistent right upper or right lower
uadrant pain, dysphagia, odynophagia, persistent vomiting,
gastrointestinal blood loss, involuntary weight loss, decel-
eration of linear growth, delayed puberty, unexplained fever,
and a family history of inflammatory bowel disease, celiac
disease, or PUD (20).
A positive noninvasive test may induce anxiety in children
with functional pain or their parents with the consequence of
referral for upper endoscopy. Therefore, diagnostic testing for
the infection should not be undertaken in these children.COMMENT:
Treatment to eliminate H pylori infection is not expected to
improve symptoms in children, except in cases of PUD. Therefore,
in children fulfilling the Rome criteria for functional abdominal
pain diagnostic testing (noninvasive or invasive) for H pylori
infection should not be undertaken (21–26). In the absence of
alarm signs or symptoms, recent updated recommendations from
the committee for ROME IV did not identify compelling evidence
to support upper endoscopy as part of the diagnostic work up (20),
discussed in comments section for recommendations 2a and 2b.
Recommendation 5a
We recommend against diagnostic testing for H pylori
infection as part of the initial investigation in children
with iron deficiency anemia (IDA).
GRADE: Strong recommendation. Quality of evi-
dence: moderate. Agreement: 93%.
Recommendation 5b
We suggest that in children with refractory IDA in
which other causes have been ruled out, testing for
H pylori during upper endoscopy may be considered.
GRADE: Weak recommendation. Quality of evi-
dence: low. Agreement: 100%.
Practice Points1. A
d
diagnosis of IDA is made when both anemia and iron
eficiency are present.
Children with IDA should be managed according to current2.
guidelines for the treatment of IDA considering the clinical
history and age of the child.
Noninvasive testing for H pylori is not recommended as part of3.
the initial investigation of IDA in children.
If upper endoscopy is clinically indicated in the management of4.
IDA refractory to iron therapy, biopsies for the diagnosis of H
pylori as outlined in recommendation 9 may be considered.
If H pylori infection is detected in the setting of refractory IDA,5.
eradication therapy for H pylori should be combined with iron
supplementation.
Noninvasive testing for H pylori in the case of refractory IDA is6.
not recommended.COMMENT:
Children are at particular risk of IDA during the first 5 years
of life because of their increased iron requirements during periods
of rapid growth (27). More than 300 million preschool and school-
age children worldwide are anemic due to iron deficiency (28). The
risk factors for IDA and H pylori are similar with many children
having concomitant IDA and H pylori infection (29,30). There is,
however, no causal relationship between IDA and H pylori. Since Copyright © ESPGHAN and NAthe last guidelines a number of methodologically well-conducted
studies have examined the relationship between iron deficiency/
IDA and H pylori, and all conclude that there is no evidence for a
causal relationship between IDA and H pylori (31–34).
The possibility that IDA may be due to blood loss associated
with PUD, or iron scavenging by the bacteria (35) must be con-
sidered in children with refractory IDA who have not responded to
initial iron supplementation therapy, rapidly relapse or who have
other alarm symptoms (34). If there are clinical indications for
upper endoscopy it is suggested that biopsies to confirm or rule out
the presence of H pylori infection may be considered. Since the
publication of the previous guidelines there are no studies that
specifically examine the relationship between refractory IDA and H
pylori. One study (36) that examined the effect of H pylori
eradication on refractory IDA was excluded because it did not
meet the inclusion criteria. Thus this recommendation remains
unchanged from previous guidelines.
Recommendation 6
We suggest that noninvasive diagnostic testing for
H pylori infection may be considered when investi-
gating causes of chronic immune thrombocytopenic
purpura (ITP).
GRADE: Weak recommendation. Quality of evi-
dence: low. Agreement: 93%.
Practice Points1. I
n
SPn the patient with chronic ITP (cITP) and thrombocytopenia,
oninvasive testing to diagnose the presence of infection should
be employed. If the noninvasive test is positive it has to be
decided on an individual basis and depending on the platelet
count whether an upper endoscopy is needed before eradication
therapy.COMMENT:
cITP (previously idiopathic thrombocytopenic purpura) in
childhood is an autoimmune disease with platelet autoantibody
formation resulting in platelet destruction and thrombocytopenia
(platelet count <100 109/L) for at least 12 months before pres-
entation. Since the last guidelines 2 small intervention studies
reported results of treating H pylori infection in the setting of
ITP in children (37,38). In both of these studies, an improvement in
platelet count occurred in a proportion of patients following H
pylori eradication. These studies were, however, nonrandomized
and included small numbers of patients with a short follow-up time.
In a small, randomized controlled trial of 22 children with H pylori
infection and cITP, increases in platelet counts were detected in
more children in the anti-H pylori treatment group; however the
follow-up period was short (39). Thus based on these limited
studies, a weak recommendation for testing and treating for H
pylori infection in the patient with cITP was included in the
guidelines. Additional well-designed interventional studies are,
however, required to provide support for this recommendation.
Recommendation 7
We recommend against diagnostic testing for H pylori
infection when investigating causes of short stature.
GRADE: strong recommendation. Quality of evi-
dence: moderate. Agreement: 79%GHAN. All rights reserved.
www.jpgn.org
JPGN  Volume 64, Number 6, June 2017 Guidelines for the Management of H pylori in Children and AdolescentsCOMMENT:
The hypothesis that eliminating H pylori infection in children
will prevent growth deficits has been investigated in few adequately
designed studies. A few new cross-sectional studies add to the
literature on associations between H pylori infection and anthro-
pometric indicators in children (40–44), with inconsistent results
across studies. Epidemiological, observation or case-control studies
are not designed to prove causation. Furthermore, both H pylori
infection and short stature are associated with low socioeconomic
status including poor nutrition. The only well-designed intervention
study in the current review period was performed in children in the
Colombian Andes in a setting of poor hygiene and high prevalence
of both malnutrition and chronic infections (45,46). Thus, further
research is needed to assess the effect of offering treatment for H
pylori in children with short stature in a North American or
European setting.
Recommendation 8
We recommend that before testing for H pylori, wait at
least 2 weeks after stopping PPIs and 4 weeks after
stopping antibiotics.
GRADE: Strong recommendation. Quality of evi-
dence: low. Agreement: 100%.
Practice Points1. P
d
wwarents and guardians should be asked about drug intake
uring the 4 weeks before testing.
These time intervals apply for primary testing to diagnose or2.
exclude H pylori infection and to monitor treatment success. It
applies for both invasive and noninvasive (urea breath test
[UBT], stool antigen) testing.
If acid suppressive therapy cannot be discontinued for3.
2 weeks because of recurrence of symptoms, changing to
an H2-receptor antagonist with discontinuation of the drug
2 days before testing may improve the sensitivity of the
diagnostic test.
Antibiotics may suppress bacterial growth and may result in4.
false-negative test results in all applied diagnostic methods
except serology (which is not recommended).COMMENT:
PPI therapy may give false-negative diagnostic test results
for H pylori infection due to suppression of H pylori replication
(47). No additional studies have been published since the last
guidelines; thus, these recommendations remain the same as the
previous guidelines.
Recommendation 9a
We recommend that the diagnosis of H pylori infection
should be based on either: positive culture or H pylori
gastritis on histopathology with at least 1 other positive
biopsy-based test.
GRADE: Strong recommendation. Quality of evi-
dence: high. Agreement: 100%.
Recommendation 9b
We recommend that at least 6 gastric biopsies should
be obtained for the diagnosis of H pylori infection
during upper endoscopy. Copyright © ESPGHAN and NA
w.jpgn.orgGRADE: Strong recommendation. Quality of evi-
dence: low. Agreement: 93%.
Practice Points
1. It is recommended that the initial diagnosis of H pylori infection
be performed using invasive gastric biopsy-based methodsS
including the following:
a. Positive bacterial culture OR
b. H pylori gastritis on histopathology using the updated
Sydney classification with at least 1 other positive test such
as RUT, or molecular-based assays where available,
including polymerase chain reaction (PCR), or fluorescentPGin situ hybridization.
e initial diagnosis of H pylori infection should not be basedTh2.
on noninvasive tests (ie, 13C-UBT, H pylori stool antigen test) or
other noninvasive methods. A positive noninvasive test,
however, supports the diagnosis in cases in which positive
histology is the only invasive test available.
At least 6 gastric biopsies should be taken for the initial3.
diagnosis of H pylori infection. Two biopsies should be obtained
from the antrum and 2 biopsies from the corpus for the
histopathological evaluation applying the updated Sydney
classification (48), at least 1 biopsy from the antrum and 1 from
the corpus for culture (if available) and at least 1 biopsy for any
additional diagnostic tests from the antrum (rapid-urease, or
molecular-based assays).
In the course of upper gastrointestinal bleeding, false-negative4.
results of gastric biopsy-based methods can occur, that is,
histopathology, culture, or RUT. Molecular diagnostic methods
may have better test accuracy in this setting (49,50).
The transport of biopsies in special transport media rather than5.
normal saline is highly recommended to enhance the success
rate for culture.COMMENT:
These recommendations remain unchanged from previous
guidelines. The current reference ‘‘criterion standard’’ for inves-
tigating H pylori–associated disease in children remains upper
gastrointestinal endoscopy with biopsies for culture, histology,
and RUT (51). None of the available diagnostic tests have 100%
accuracy. Bacterial culture is, however, 100% specific. The positive
predictive value of a diagnostic test rapidly decreases if the
prevalence of the infection in the population is low, which is the
situation in children in most European and North American
countries. Therefore, we recommend that the diagnosis of H pylori
infection be based on 2 tests and not only on a positive histology.
During the current review period, Seo et al (52) reported the rate of
RUT positivity in 255 H pylori–infected children. The authors
found that the sensitivity of RUT increased with age (being lowest
in the 0–4-year age group) and with the number of biopsies,
whereas the time of an RUT to turn positive took longer in the
younger age group. The authors explain their findings by a lower
bacterial density in children compared to adolescents and adults.
Similar to previous findings, a recent study reported that antral
nodularity remains a useful diagnostic predictor of H pylori gastritis
in children (53).
Recommendation 10
We recommend against antibody-based tests (immu-
noglobulin G [IgG], IgA) for H pylori in serum, whole
blood, urine, and saliva in the clinical setting.HAN. All rights reserved.
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Practice Points
1. These antibody-based tests should not be used to detect the
presence of active H pylori infection or for use in post-treatment99evaluation in children or adolescents.COMMENT:
These recommendations remain unchanged from previous
guidelines.
Recommendation 11
We recommend that antimicrobial susceptibility be
obtained for the infecting H pylori strain(s) and, the
eradication treatment tailored accordingly.
GRADE: Strong recommendation. Quality of evi-
dence: low. Agreement: 86%.
Practice Points1. H
c
pylori antimicrobial susceptibility testing should be based on
ulture biopsy–based methods (E-test or agar dilution) or
molecular biopsy–based techniques (real-time PCR, fluor-
escent in situ hybridization).
The transport of biopsies in special transport media will2.
enhance the success rate for culture.
Molecular methods, especially commercially available kits3.
based on real-time PCR, are suitable to detect H pylori and
clarithromycin resistance in gastric biopsy specimens or gastric
juice. At this stage these techniques cannot be recommended for
detection of antibiotic resistance in stool.
To increase the sensitivity for detecting antimicrobial resistance4.
of H. pylori strains in children colonized with different
resistance patterns it is recommended that gastric biopsies
for culture- and molecular-based tests be obtained from at least
2 different locations (ie, antrum and body). The biopsies can be
sent to the laboratory in the same jar.COMMENT:
Antimicrobial resistance patterns vary depending on
national/geographic regions and are a major factor in determining
the success of eradication therapy (54–61). Treatment failure will
result in increased healthcare utilization, and likely puts the child
through additional unnecessary procedures and therapies, and the
associated risks. Moreover, eradication failure increases the risk of
antibiotic resistance of the infecting H pylori strains, thereby
reducing the likelihood of successful eradication (55,56). Devel-
opment of antibiotic resistance may also occur if children are on
long-term antibiotics for other comorbidities.
In many countries primary clarithromycin resistance has
increased to levels above the recommended threshold (15%) for
use as a first-line agent for H pylori infection (54). Furthermore,
antibiotic resistance rates of H pylori can vary among different
regions within the same country (58). Thus, national/regional
antibiotic resistance data could be used to guide treatment regimens
for H pylori infection (54). In fact, increasing antimicrobial resist-
ance likely explains the reduction in efficacy of clarithromycin
containing regimens over time. Resistance to metronidazole has Copyright © ESPGHAN and NA
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also increased in some populations and regions (55,60). In addition,
multiple strains with different antibiotic resistance profiles can exist
within the same individual (62). In adults, treatment tailored to
antimicrobial susceptibility reduces the risk of treatment failure
compared with empirical triple therapy (63). Few comparative data
including only a small number of children exist in the pediatric
literature.
Recommendation 12
We recommend that the effectiveness of first-line
therapy be evaluated in national/regional centers.
GRADE: Strong recommendation. Quality of evi-
dence: low. Agreement: 100%.
Practice Points1. A
c
SPs antimicrobial susceptibility testing is not available in all
enters, we propose that national/regional effectiveness of
H pylori eradication regimens in children and adolescents be
evaluated if possible.COMMENT:
Treatment failure of H pylori eradication regimens in rou-
tine practice is often associated with inappropriate choice of
treatment regimen, poor adherence, and antimicrobial resistance.
To avoid further investigations, and induction of secondary resist-
ance in the infecting H pylori strains, a primary success rate for
eradication should be more than 90% in per-protocol analysis (54).
This goal is not achieved in most current published treatment trials
in children (63–68). Therefore, benchmarking is a necessity to
assess the local performance of the prescribed regimens and to
minimize the risk of treatment failure. This is of particular import-
ance in areas in which antimicrobial susceptibility testing is
not available.
Recommendation 13
We recommend that the physician explain to the
family the importance of adherence to the anti–
H pylori therapy to enhance successful eradication.
GRADE: Strong recommendation. Quality of evi-
dence: moderate. Agreement: 86%.
Practice Points1. P
d
atient information leaflets with individualized schedules for
rug intake may improve adherence.
COMMENT:Lack of adherence is a significant risk factor for failure of
therapy (6). A recent study published outside of the review period
demonstrated that a high success rate for eradication therapy was
achieved only in the subset of infected children who took at least
90% of the prescribed eradication therapy (67). Recommended
eradication protocols are composed of at least 3 drugs given for
10 to 14 days. In addition, therapy-related adverse effects, although
mostly minor, are quite frequent. Therefore, a proper and detailed
explanation of the recommended therapy, potential side effects, and
importance of adherence to parents and children is critical to the

















FIGURE 1. Algorithm for selection of eradication therapy for H pylori
JPGN  Volume 64, Number 6, June 2017 Guidelines for the Management of H pylori in Children and AdolescentsRecommendation 14
We recommend the following as first-line therapy for
H pylori infection as outlined in Table 2.
GRADE: Strong. Quality of evidence: moderate to low
for suggested regimens; low for duration; Agreement:
100%.
Practice Pointsinfection in children based on knowledge of antibiotic susceptibility.
PPI ¼ proton pump inhibitor.
1. I
m
wwf the strain is susceptible to clarithromycin (CLA) and to
etronidazole (MET), triple therapy (PPI, amoxicillin [AMO],
CLA) for 14 days is the preferred choice. In comparison with
sequential therapy, this regimen will not induce resistance to
metronidazole. In case of treatment failure with PPI, AMO, and
CLA a switch to PPI, AMO, and MET can be made without
further susceptibility testing.
Sequential therapy for 10 days (PPI with AMO for 5 days2.
followed by PPI with CLA and MET for 5 days with doses given
in Table 3) is equally effective in patients infected with fully
susceptible strains. It, however, has the disadvantage of
exposing the child to 3 different antibiotics. Sequential therapy
should not be given if the strain is resistant to METor CLA, or if
susceptibility testing is not available. The most recent adult
guidelines recommend against the use of sequential therapy as
first- or second-line therapy (69,70).
Doses of PPI and antibiotics should be calculated based on the3.
bodyweight as shown in Table 3.
A higher degree of acid suppression improves the success rate of4.
amoxicillin- and clarithromycin-based therapy. Younger chil-
dren need a higher PPI dose per kg bodyweight compared to
adolescents and adults to obtain sufficient acid suppression.
Esomeprazole and rabeprazole are less susceptible to5.
degradation by rapid metabolizers with CYP2C19 genetic
polymorphism, and therefore, may be preferred when available.
Rapid metabolizers are more frequent in the Caucasian
population (56%–81%) compared to Asians.
The PPI dose given in the table refers to esomeprazole and6.
omeprazole and should be adapted if other PPIs are used. PPIs
should be preferentially given at least 15 minutes before meal.
For children younger than 8 years, bismuth quadruple therapy7.
refers to bismuth, PPI, AMO, and MET. In children older than 8
years, bismuth quadruple therapy refers to bismuth, PPI, MET,
and tetracycline.
The routine addition of either single or combination probiotics8.
to eradication therapy to reduce side effects and/or improve
eradication rates is not supported by current evidence.COMMENT:
Treatment success is negatively affected if the strain is
resistant to one of the antibiotics used. Thus recommended therapies
should be based on knowledge of antibiotic susceptibility testing
(Fig. 1). If primary culture and susceptibility testing is not available,
then clarithromycin-based triple therapy should not be used as part
of first-line therapy due to high rates of clarithromycin resistance
rates worldwide (55–61).
The previous optimism for the use of 10-day sequential
therapy (PPI with AMO for 5 days followed by PPI with CLA
and MET for 5 days) in treatment naı̈ve patients has now been
questioned by additional studies in both children (64–66) and adults
(68). A meta-analysis of pediatric studies concluded that a 10-day
sequential therapy was superior to 7-day standard triple therapy
(relative risk 1.17, 95% confidence interval: 1.071.28), but Copyright © ESPGHAN and NA
w.jpgn.orgperformed similar to 10- or 14-day triple therapy (65). In an open
label, prospective multicenter European study of 165 children,
eradication rates with sequential therapy were only 56% when
clarithromycin resistance was present (64). Thus, current evidence
indicates that sequential therapy should not be recommended in
treatment-naı̈ve children when antibiotic susceptibility of the
infecting strain is not known. A recently published European
pediatric study (67) that was outside the time frame of our review
and not included in our analysis, lends support to the recommen-
dation above. In the present study, primary eradication rates with a
high-dose sequential 10-day regimen in children with strains
susceptible to both clarithromycin and metronidazole were
85.8% in the intention to treat analysis. In the presence of metro-
nidazole or clarithromycin resistance these rates, however, dropped
to 73.3% and 71.1%, respectively. In addition to antibiotic resist-
ance, the other major factor affecting eradication in the present
study was drug intake of <90% of the prescribed medication dose.
Although there are no specific pediatric studies addressing this
therapy, a 14-day tailored triple therapy is recommended when H
pylori stains are resistant to 1 antimicrobial agent (eg, clarithro-
mycin or metronidazole).
There are no new well-designed pediatric studies regarding
the use of bismuth in eradication protocols since the last guidelines.
One retrospective study in Korean children compared eradication
rates with bismuth-based quadruple therapy including omeprazole,
amoxicillin, and metronidazole for 7 days with standard triple
therapy consisting of omeprazole, amoxicillin, and clarithromycin
for 14 days (71). Bismuth-based quadruple therapies had higher
eradication rates than standard triple therapy, particularly in the
more recent era of 2010 to 2012. Recent meta-analyses in adult
subjects indicate that bismuth-based therapy is effective (68). Thus,
based on previous literature and adult studies we recommend
bismuth quadruple therapy (where available) in children if H pylori
antimicrobial susceptibility is unknown or in the setting of dual
resistance to clarithromycin and metronidazole. The other recom-
mended therapy in this setting is high-dose amoxicillin triple
therapy with metronidazole (Table 4). The evidence supporting
this regimen is, however, limited. In 1 small open multicenter
European study of children infected with clarithromycin- and
metronidazole-resistant strains, eradication rates using high-dose
amoxicillin and PPI with metronidazole was 66% in intention to
treat analysis (72).
In adult patients, a recent meta-analysis showed that con-
comitant quadruple therapy (PPI and amoxicillin, metronidazole,
and clarithromycin given for 10 to 14 days) was one of the most
effective treatments, with a high eradication rate and acceptable
frequency of adverse events (73). The most recent adult inter-
national practice guidelines recommend concomitant therapy as a
first-line option (69,70). Currently no studies assessing concomitantSPGHAN. All rights reserved.
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studies should assess this therapy in children and adolescents. In
children with primary double resistance to clarithromycin and
metronidazole, concomitant therapy may be a better option com-
pared to triple therapy with high-dose amoxicillin.
There are limited well-designed studies in children and
adolescents with respect to the optimal duration of anti–H pylori
therapy. Regardless of the length of therapy, the choice of anti-
biotics or the dosing schedule, eradication rates for most anti–H
pylori therapies are less than the recommended 90% per protocol
treatment success. Meta-analyses of optimal duration of H pylori
eradication therapy in adults have been performed and show that
increasing the duration of therapy enhances eradication rates (74).
With respect to triple therapy, a recent systematic review and
network analysis of studies in adults showed that 14-day duration
of treatment improves eradication rates compared to 10-day, and
both are superior to 7-day treatment (68). Of note, longer duration
therapies were associated with increased rate of adverse events in
the present study.
The role of supplemental probiotic therapy to reduce adverse
effects, improve adherence, and, thereby, increase efficacy of H
pylori eradication regimens remains controversial. Several meta-
analyses have attempted to address this (75–77). Although these
studies suggest that there may be a benefit for reduction of adverse
effects and improved efficacy when added to H pylori eradication
therapy, the studies included in these meta-analyses employ differ-
ent probiotic strains and concentrations making it difficult to draw
meaningful conclusions. Therefore, additional sufficiently powered
pediatric studies with specific probiotic strains should be performed
to develop more reliable conclusions about the benefit of probiotics
in H pylori eradication regimens.
There is no evidence to suggest that testing and treating
family members for H pylori infection reduces the risk of reinfec-
tion. Of note, recent vaccine trials suggest that in areas with high
endemic rates of infection, infection rates are low in children older
than 6 years (4).
Recommendation 15a
We recommend that the outcome of anti–H pylori
therapy be assessed at least 4 weeks after completion
of therapy.
GRADE: strong recommendation. Quality of evi-
dence: moderate. Agreement: 100%.
Recommendation 15b
We recommend that one of the following tests be
used to determine whether H pylori treatment was
successful:
(1) The 13C-UBT.
(2) A 2-step monoclonal stool H pylori antigen test.
GRADE: Strong recommendation. Quality of evi-
dence: high. Agreement: 93%.
Practice Points1. T
t
10he relief of symptoms is not an indicator for successful
reatment. Therefore, all children treated for H pylori should be
assessed for treatment success with a reliable test.
Endoscopy and biopsy-based tests to confirm eradication are2.
rarely needed in pediatric patients with uncomplicated PUD.
Gastric and duodenal peptic ulcers have a low risk for relapse
with clearance of the infection. Copyright © ESPGHAN and NA
003. T
y
SPhe C-UBT may give false-positive results in children
ounger than 6 years of age because of the lower distribution
volume and different CO2 production rate (78–80). False-
positive results may also be due to technical difficulties in
performing 13C-UBT in young children because they are often
unwilling to swallow the substrate and oral urease–producing
organisms can then split the substrate. This has little relevance
in clinical practice in which eradication therapy is, however,
rarely indicated in children younger than 6 years.
The use of 14C-UBT is not recommended in children.4.
5. The accuracy of the 2-step monoclonal stool antigen test is
comparable to the 13C-UBT and performance is unrelated to
age. This test is not available (licensed) in North America.
The polyclonal stool antigen test has a lower accuracy6.
compared to the 13C-UBT and the monoclonal stood test, but
may be an option in situations when neither of the other 2 tests
are available (81,82).
Rapid office-based stool tests have a lower performance7.
compared to laboratory-based tests.COMMENT:
When considering a test for cure, it is important to employ
the most accurate test for active infection (78). In most clinical
settings, noninvasive testing, either 13C-UBT or fecal antigen
testing should be employed to ensure cure of infection has been
achieved (78). The 13C-UBT is well validated against invasive tests
and performs well even with a variety of test protocols (79,80). In
contrast, fecal tests depend on the antigen used and may differ in
their performance (81–86). For both 13C-UBT and fecal antigen
testing, false-negative results can occur when medications are taken
that decrease the bacterial load or suppress gastric acid (78).
Therefore testing for cure should be performed at least 4 weeks
after completion of eradication therapy to avoid false-
negative results.
Recommendation 16
We recommend that when H pylori treatment fails,
rescue therapy should be individualized considering
antibiotic susceptibility, the age of the child, and
available antimicrobial options.
GRADE: Strong recommendation. Quality of evi-
dence: low. Agreement: 93%.
Practice Points1. See Table 5 for specific recommendations for rescue therapy.COMMENT:
In comparison with adults, reduced options for rescue
therapy exist in children, further emphasizing the need for the
selection of initial regimens with the best chance of success. In
patients who have previously failed H pylori eradication therapy,
the choice of rescue therapy should consider initial antibiotic
susceptibility status (if known) and the first-line regimens employed
(Table 5). Where possible, rescue therapy should be based on
antibiotic resistance profiles. Antibiotics with a high likelihood
of the infecting strain to develop secondary resistance (eg, clari-
thromycin, metronidazole) should be avoided if they were
employed in the initial regimen. Studies in adults suggest that
increasing acid suppression and metronidazole dose may improveGHAN. All rights reserved.
www.jpgn.org
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addressing this issue for rescue therapy in children, employing
higher dosages of PPI and metronidazole may be considered. As
described in recommendation 14, 1 study showed that in children
infected with clarithromycin- and metronidazole-resistant strains,
the eradication rate using high dose amoxicillin and PPI with
metronidazole was 66% in intention to treat analysis (72). In a
recent multicenter, open-label, single-arm, clinical trial (82) of H
pylori–positive adults who had failed more than one previous
course of omeprazole-amoxicillin-clarithromycin therapy, a
quadruple regimen of bismuth, metronidazole, and tetracycline
plus omeprazole produced a high eradication rate (up to 95.8%).
As expected, these authors concluded that bismuth-based regi-
men offers an effective option as rescue therapy (88).
SUMMARY
Because of the unacceptably low H pylori eradication rates in
children reported in the literature from different countries, and the
increasing rates of antibiotic resistance, these guidelines now focus
on prescribing treatment for H pylori in children only when it is
clinically indicated, or when following discussion with parents it is
deemed appropriate to treat an incidental finding of H pylori in
children (Table 6). Previous guideline recommendations of triple or
sequential therapy for treatment-naı̈ve H pylori–infected children
and adolescents can no longer be supported. Instead, to achieve an
initial eradication success rate of 90% and higher, therapy should be
based on knowledge of antibiotic resistance profiles and therapy
tailored accordingly using sufficiently high doses and treatment Copyright © ESPGHAN and NA
TABLE 6. Highlights of changes in new guidelines in comparison to the p
New recommendations
1. Who to test for H pylori infection
Testing for H pylori during endoscopy should only be performed if intendin
treat
Testing for H pylori is not recommended in the initial investigation of iron
deficiency anemia
Weak recommendation to consider noninvasive testing for H pylori infection in
setting of chronic ITP
Recommend against testing in the setting of short stature
Removal of recommendation for testing in the setting of family history of gas
cancer or MALT, as rarely encountered
2. How to test for H pylori
Six gastric biopsies for either (a) histopathology (H pylori–positive gastritis) p
at least 1 other positive biopsy–based test or (b) positive culture.
3. Who to treat with H pylori infection
If H pylori is an incidental finding at endoscopy treatment may be considere
following careful discussion of the risks and benefits of H pylori treatment with
patient/parents
Weak recommendation for patient with chronic ITP
4. How to treat infected patients
Evaluation of effectiveness of first-line therapy in national/regional centers
Differences in first-line recommended therapies and dosing (see Table 2 and
algorithm)
Tailored treatment based on antibiotic sensitivity where available.
Duration of therapy 14 days
Higher dose of PPI, particularly in younger children, with doses from 1.5 to 2.5
kg bodyweight and day
Recommendation that physician explain to the patient/ family the importanc
adherence
ITP¼ immune thrombocytopenic purpura; MALT¼mucosa-associated lymp
www.jpgn.orgdurations of 10 to 14 days. The importance of adherence for optimal
successful eradication should be emphasized to the parents and
child. Clarithromycin-containing regimens should be restricted to
those infected with clarithromycin-susceptible strains. When anti-
biotic susceptibility profiles are not known, high-dose triple therapy
with PPI, amoxicillin, and metronidazole for 14 days is recom-
mended as first-line therapy. Bismuth-based quadruple therapy can
also be considered for first-line therapy in countries where it is
licensed for use in children. As with the previous guidelines, testing
for cure should be performed with either the C13-UBT or a fecal
antigen test at least 4 weeks after therapy to avoid false-negative
results. Second-line therapies present a real challenge in children
due to the limited number of antibiotics that are appropriate to use in
children. Second-line therapies should take into consideration the
antibiotics employed for the initial therapy, duration of treatment,
and, where possible, should be based on antibiotic resistance
profiles.
Future Directions for the Management of
H pylori–infected Children
Future studies should focus on obtaining antibiotic resistance
rates across regions to help direct optimal therapy. In addition, high-
quality studies evaluating novel approaches and therapies in chil-
dren including quadruple concomitant therapy (PPI and amoxicil-
lin, metronidazole, and clarithromycin given for 10–14 days),
bismuth-based regimens, and the role of supplemental probiotics
are needed. Importantly, studies of prevention of infection with
optimization of vaccine strategies should be performed.SPGHAN. All rights reserved.
revious guidelines
Previous recommendations
g to Not addressed
Not addressed
the Insufficient evidence that infection is causally related to ITP
Insufficient evidence that infection is causally related to short
stature
tric Consider testing in the setting of family history of gastric
cancer or MALT
lus Biopsies from corpus and antrum for histopathology plus rapid
urease test or culture
d
the
When H pylori is detected by biopsy-based methods in absence
of PUD, treatment may be considered
Surveillance of antibiotic resistance rates in different countries
First-line therapy options: standard triple,
bismuthþ amoxicillinþ imidazole or sequential
In areas with high clarithromycin resistance, perform
susceptibility testing for clarithromycin to tailor its use
Duration of therapy 7–14 days
mg/ PPI dose ranging from 1 to 2 mg/kg bodyweight and day
e of Not a specific recommendation, addressed in discussion
hoid tissue; PPI¼ proton pump inhibitor; PUD¼ peptic ulcer disease.
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